Amphotericin B deoxycholate
PreclinicalSmall molecule
Merck & Co.Amphotericin B deoxycholate is one of 3 small molecule programs targeting Cryptococcal Meningitis. It is currently in Preclinical.
1
Indications
13
Total Trials
1
Active Trials
2
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
2 competitors in Cryptococcal Meningitis
#DrugCompanyPhaseTrials
1Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Amphotericin B deoxycholate
Merck & Co.Preclinical
Amphotericin B Colloidal Dispersion
PPeking Union Medical College Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Visceral Leishmaniasis5 trials
Combination Therapy in Indian Visceral Leishmaniasis
Completed·—·Phase 3·NCT00523965·624 enrolled
Show 2 more trials
Candidiasis2 trials
Cryptococcal Meningitis2 trials
Aspergillosis1 trial
Comparison of Voriconazole and Amphotericin B in Treating Patients With Aspergillosis
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00003031·212 enrolled
2 more indications
Neutropenia1 trial
Chronic Pulmonary Aspergillosis1 trial
A Randomized Controlled Trial to Compare Nebulized Amphotericin B and Nebulized Normal Saline as Maintenance in Increasing Time to Relapse in Patients With Chronic Pulmonary Aspergillosis Treated With 12 Months of Oral Itraconazole
Recruiting·PPost Graduate Institute of Medical Education and Research, Chandigarh·Phase 3·NCT06447402·196 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Amphotericin B deoxycholate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company